Leonor Mendonça Almeida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Leonor Mendonça Almeida has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
A. Magalhães
Pulmonology Department, Centro Hospitalar de São João, Porto, Portugal
1 shared publicationA. Morais
Pulmonology Department, Centro Hospitalar de São João, Porto, Portugal; Faculdade de Medicina da Universidade do Porto, Porto, Portugal
1 shared publicationAdelina Amorim
Pulmonology Department of ULS São João, Cystic Fibrosis Reference Center, ULS São João, Rua de Miguel Bombarda 234, 4050-377, Porto, Portugal; Faculty of Medicine, University of Porto (FMUP), Rua de Miguel Bombarda 234, 4050-377, Porto, Portugal
1 shared publication- Ana Luisa Pereira
Pharmaceutical Service, ULS São João, Rua de Miguel Bombarda 234, 4050-377, Porto, Portugal
1 shared publication Ana Luísa Fernandes
Pulmonology Department, Hospital Pedro Hispano, Matosinhos, Portugal
1 shared publicationAnabela Marinho
Pulmonology department, Centro Hospitalar e Universitário São João, Porto, Portugal
1 shared publication
Latest Publications
- 15 July 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 246, 108238
N1303K (p.Asn1303Lys) variant: Expanding frontiers in the treatment of cystic fibrosis
- 15 July 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 246, 108238
N1303K (p.Asn1303Lys) variant: Expanding frontiers in the treatment of cystic fibrosis
- Open Access
- 8 December 2022
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 16
Mortality risk prediction with ILD-GAP index in a fibrotic hypersensitivity pneumonitis cohort
Background: Fibrotic hypersensitivity pneumonitis (fHP) is associated with significant morbidity and mortality. Interstitial lung disease–gender-age-physiology (ILD-GAP) performance in fHP outside the initial cohort was never performed. Aim: To assess the ILD-GAP index’s ability to predict mortality in a Portuguese cohort of patients with fHP and analyse whether other clinical variables add value. Methods: Retrospective analysis of fHP cohort in two Portuguese ILD centres. The baseline ILD-GAP index was calculated. Survival was analysed in months; mortality was the primary outcome. Univariate and multivariate analyses to identify mortality risk factors were performed. Results: A total of 141 patients were included. Fifty-three patients (37.6%) died during the follow-up. The usual interstitial pneumonia (UIP) pattern was found in 49.6%, and their survival was inferior to non-UIP [32 months (interquartile range, IQR = 19, 60) versus 52 months (IQR = 28, 98), p = 0.048]. Patients with an ILD-GAP index higher than three double their risk of mortality [hazard ratio (HR) = 6.48, 95% confidence interval (CI) = (3.03–13.96)] when compared with the patients with an index between 2 and 3 [HR = 3.04, 95% CI = (1.62–5.71)] adjusting for acute exacerbation history. Even though UIP patients had worse survival, it did not reach statistical significance when UIP pattern was added to this model. Acute exacerbation history was an independent risk factor for mortality; however, ILD-GAP still predicted mortality after adjusting for this factor. PaO2 and 6-minute walk test desaturation were not significant risk factors. Conclusion: ILD-GAP index is a good predictor for mortality in fHP, even after adjusting for other mortality risk factors.
- 8 December 2022
- Published by SAGE Publications in Therapeutic Advances in Respiratory Disease
- Vol. 16
Open AccessMortality risk prediction with ILD-GAP index in a fibrotic hypersensitivity pneumonitis cohort
Background: Fibrotic hypersensitivity pneumonitis (fHP) is associated with significant morbidity and mortality. Interstitial lung disease–gender-age-physiology (ILD-GAP) performance in fHP outside the initial cohort was never performed. Aim: To assess the ILD-GAP index’s ability to predict mortality in a Portuguese cohort of patients with fHP and analyse whether other clinical variables add value. Methods: Retrospective analysis of fHP cohort in two Portuguese ILD centres. The baseline ILD-GAP index was calculated. Survival was analysed in months; mortality was the primary outcome. Univariate and multivariate analyses to identify mortality risk factors were performed. Results: A total of 141 patients were included. Fifty-three patients (37.6%) died during the follow-up. The usual interstitial pneumonia (UIP) pattern was found in 49.6%, and their survival was inferior to non-UIP [32 months (interquartile range, IQR = 19, 60) versus 52 months (IQR = 28, 98), p = 0.048]. Patients with an ILD-GAP index higher than three double their risk of mortality [hazard ratio (HR) = 6.48, 95% confidence interval (CI) = (3.03–13.96)] when compared with the patients with an index between 2 and 3 [HR = 3.04, 95% CI = (1.62–5.71)] adjusting for acute exacerbation history. Even though UIP patients had worse survival, it did not reach statistical significance when UIP pattern was added to this model. Acute exacerbation history was an independent risk factor for mortality; however, ILD-GAP still predicted mortality after adjusting for this factor. PaO2 and 6-minute walk test desaturation were not significant risk factors. Conclusion: ILD-GAP index is a good predictor for mortality in fHP, even after adjusting for other mortality risk factors.
- Open Access
- 1 April 2021
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 91 (3)
Non-invasive ventilation in the elderly – never too late!
Dear Editor, Practising evidence-based medicine in an ageing population is challenging. Nevertheless, using age as a diagnostic or therapeutic procedure contraindication is less and less common. Domiciliary non-invasive ventilation (NIV) in chronic respiratory failure patients has been largely used; however, data from older people is scarce...
- 1 April 2021
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 91 (3)
Open AccessNon-invasive ventilation in the elderly – never too late!
Dear Editor, Practising evidence-based medicine in an ageing population is challenging. Nevertheless, using age as a diagnostic or therapeutic procedure contraindication is less and less common. Domiciliary non-invasive ventilation (NIV) in chronic respiratory failure patients has been largely used; however, data from older people is scarce...
- 1 April 2021
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 57 (4) , 309-311
Massive Pulmonary Thrombosis Following Haemoptysis in Type IV Ehlers–Danlos Syndrome
- 1 April 2021
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 57 (4) , 309-311
Massive Pulmonary Thrombosis Following Haemoptysis in Type IV Ehlers–Danlos Syndrome
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Non-invasive ventilation in the very old – what to expect?
Introduction: Evidence-based medicine in aging population is challenging. Nevertheless, using age as an contraindication is less and less common. Non-invasive ventilation (NIV) in the chronic setting has been largely used, however data from older people is scarce. Methods: Retrospective analysis of NIV adapted patients with ≥75 years old in one year in a chronic setting. Evaluation of efficacy and adhesion at 12 months. Results: The were 261 in-lab adaptations to NIV and 82 (31.4%) performed in patients older than 75 were included. The majority were male (43|52.4%), mean age of 82.1±5 years old. Indications to treatment were: Obstructive Sleep Apnoea with hypoventilation (23|28%), COPD (17|20.7%) and Obesity-hypoventilation syndrome (16|19.5%). Most patients (72%) presented with hypercapnic respiratory failure and were adapted to NIV in spontaneous-temporized mode (91.5%) with mean IPAP of 19.2±4.4 mmHg and EPAP of 7.47±2.4 mmHg. Adhesion at 12 months was 83.9% with 7:28h/night. Twenty-eight (34%) suspended NIV during follow-up. In this group of patients, there was a significant reduction in PaCO2 at 30 days (51±10.5 mmHg vs 44.6±6.9 mmHg, p<0.001) and at 12 months (42.3±7.0mmHg, p<0.001). A reduction in hospitalizations for respiratory failure was also observed (1.02 vs 0.29/year, p<0.001). Sixteen patients died in the first year (19.5%). When two age groups - <85 and ≥85 – were compared, there were no significant differences between groups in none of the analysed variables. Conclusion: NIV is an effective treatment even in very old patients, correcting hypercapnia and reducing hospitalization, reinforcing that age shouldn’t be an exclusion criterion for this therapeutic option.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Non-invasive ventilation in the very old – what to expect?
Introduction: Evidence-based medicine in aging population is challenging. Nevertheless, using age as an contraindication is less and less common. Non-invasive ventilation (NIV) in the chronic setting has been largely used, however data from older people is scarce. Methods: Retrospective analysis of NIV adapted patients with ≥75 years old in one year in a chronic setting. Evaluation of efficacy and adhesion at 12 months. Results: The were 261 in-lab adaptations to NIV and 82 (31.4%) performed in patients older than 75 were included. The majority were male (43|52.4%), mean age of 82.1±5 years old. Indications to treatment were: Obstructive Sleep Apnoea with hypoventilation (23|28%), COPD (17|20.7%) and Obesity-hypoventilation syndrome (16|19.5%). Most patients (72%) presented with hypercapnic respiratory failure and were adapted to NIV in spontaneous-temporized mode (91.5%) with mean IPAP of 19.2±4.4 mmHg and EPAP of 7.47±2.4 mmHg. Adhesion at 12 months was 83.9% with 7:28h/night. Twenty-eight (34%) suspended NIV during follow-up. In this group of patients, there was a significant reduction in PaCO2 at 30 days (51±10.5 mmHg vs 44.6±6.9 mmHg, p<0.001) and at 12 months (42.3±7.0mmHg, p<0.001). A reduction in hospitalizations for respiratory failure was also observed (1.02 vs 0.29/year, p<0.001). Sixteen patients died in the first year (19.5%). When two age groups - <85 and ≥85 – were compared, there were no significant differences between groups in none of the analysed variables. Conclusion: NIV is an effective treatment even in very old patients, correcting hypercapnia and reducing hospitalization, reinforcing that age shouldn’t be an exclusion criterion for this therapeutic option.
- Open Access
- 30 January 2018
- Published by Taylor & Francis in Pulmonology
- Vol. 24 (1) , 23-31
Learning curve for transbronchial lung cryobiopsy in diffuse lung disease
Transbronchial lung cryobiopsy (TBLC) is increasingly used in the diagnosis of diffuse lung disease (DLD), but no data have yet been published on the learning curve associated with this technique. To evaluate diagnostic yield, lung tissue sample length and area, and procedure-related complications in a cohort of TBLC procedures to define the learning curve and threshold for proficiency. Retrospective analysis of the first 100 TBLCs performed in different segments of the same lobe in patients with suspected DLD. We compared diagnostic yield, sample length and area, and complications between consecutive groups of patients. The overall diagnostic yield for TBLC was 82%. Median sample length was 5.4mm (IQR, 5-6) and median area was 19.5mm2 (IQR, 13.3-25). Pneumothorax was the most common complication (18%). On comparing the two groups of 50 consecutive patients, a significant difference was found for diagnostic yield (74% vs 90%; p=0.04), sample length (5.0mm [2.5-16] vs 6.0mm [4-12;] p<0.01) and area (17.5mm2 [6-42] vs 21.5mm2 [10-49]; p<0.01). Logarithm regression was applied to median diagnostic yield and sample length and area for groups of 10 consecutive patients to define the learning curve, which plateaued after approximately 70 procedures. Our findings suggest that proficiency in TBLC is achieved at approximately the 70th procedure; however they need to be validated in more series and cohorts.
- 30 January 2018
- Published by Taylor & Francis in Pulmonology
- Vol. 24 (1) , 23-31
Open AccessLearning curve for transbronchial lung cryobiopsy in diffuse lung disease
Transbronchial lung cryobiopsy (TBLC) is increasingly used in the diagnosis of diffuse lung disease (DLD), but no data have yet been published on the learning curve associated with this technique. To evaluate diagnostic yield, lung tissue sample length and area, and procedure-related complications in a cohort of TBLC procedures to define the learning curve and threshold for proficiency. Retrospective analysis of the first 100 TBLCs performed in different segments of the same lobe in patients with suspected DLD. We compared diagnostic yield, sample length and area, and complications between consecutive groups of patients. The overall diagnostic yield for TBLC was 82%. Median sample length was 5.4mm (IQR, 5-6) and median area was 19.5mm2 (IQR, 13.3-25). Pneumothorax was the most common complication (18%). On comparing the two groups of 50 consecutive patients, a significant difference was found for diagnostic yield (74% vs 90%; p=0.04), sample length (5.0mm [2.5-16] vs 6.0mm [4-12;] p<0.01) and area (17.5mm2 [6-42] vs 21.5mm2 [10-49]; p<0.01). Logarithm regression was applied to median diagnostic yield and sample length and area for groups of 10 consecutive patients to define the learning curve, which plateaued after approximately 70 procedures. Our findings suggest that proficiency in TBLC is achieved at approximately the 70th procedure; however they need to be validated in more series and cohorts.